ImmunogenX Acquires Alvine Pharmaceuticals

Newport Beach-based ImmunogenX, which develops treatments for the diagnosis and treatment of autoimmune and gastrointestinal diseases like celiac disease, said late Tuesday that it has acquired the assets of Alvine Pharmaceuticals. Financial terms of the acquisition were not announced by the company. ImmunogenX said it acquired the non-cash assets of Alvine Pharmaceutiacls, including Latiglutenase, a candidate for treating celiac disease.